{
    "clinical_study": {
        "@rank": "116047", 
        "arm_group": [
            {
                "arm_group_label": "BAY94-8862 (1.25 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BAY94-8862 (2.5 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BAY94-8862 (5 mg )", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BAY94-8862 (7.5 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BAY94-8862 (10 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "BAY 94-8862 (15 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BAY 94-8862 (20 mg)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the\n      clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive,\n      double-blind, placebo-controlled, parallel-group design.\n\n      Primary objective of the study is investigate the change of Urinary Albumin to Creatine\n      Ratio (UACR) after treatment with different oral doses of BAY94-8862 given once daily from\n      baseline to Visit 8 (Day 90)"
        }, 
        "brief_title": "Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Nephropathies", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Diabetic Nephropathies", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese subjects with type 2 diabetes mellitus and a clinical diagnosis of DN\n             (Diabetic Nephropathy) treated with at least the minimal recommended dose of an\n             Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blocker\n             (ARB)\n\n          -  Subjects with a clinical diagnosis of Diabetic Nephropathy (DN) based on at least 1\n             of the following criteria:\n\n               -  Persistent very high albuminuria defined as Urinary Albumin to Creatine Ratio\n                  (UACR) of >/=300 mg/g (>/=34 mg/mmol) in 2 out of 3 first morning void samples\n                  and estimated glomerular filtration rate (eGFR) >/=30 mL/min/1.73 m2 but <90\n                  mL/min/1.73 m2 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) or\n\n               -  Persistent high albuminuria defined as UACR of >/=30 mg/g but <300 mg/g (>/=3.4\n                  mg/mmol but <34 mg/mmol) in 2 out of 3 first morning void samples and eGFR>/=30\n                  mL/min/1.73 m2 but <90 mL/min/1.73 m2 (CKD-EPI)\n\n          -  Serum potassium </=4.8 mmol/L at both the run-in visit and the screening visit\n\n        Exclusion Criteria:\n\n          -  Non-diabetic renal disease (confirmed by biopsy)\n\n          -  Known bilateral clinically relevant renal artery stenosis (>75%)\n\n          -  Glycated hemoglobin(HbA1c) >12% at the run-in visit or the screening visit\n\n          -  UACR >3000 mg/g (339 mg/mmol) in any of the urinary first morning void samples at the\n             run-in visit or screening visit\n\n          -  Hypertension with mean sitting systolic blood pressure (SBP) >/=180 mmHg or mean\n             sitting diastolic blood pressure (DBP) >/=110 mmHg at the run-in visit or mean\n             sitting SBP >/=160 mmHg or mean sitting DBP >/=100 mmHg at the screening visit\n\n          -  Subjects with a clinical diagnosis of heart failure with reduced ejection fraction\n             (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the\n             run-in visit\n\n          -  Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or\n             potassium-sparing diuretic"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968668", 
            "org_study_id": "16816"
        }, 
        "intervention": [
            {
                "arm_group_label": "BAY94-8862 (1.25 mg)", 
                "description": "1.25 mg BAY94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY94-8862", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (2.5 mg)", 
                "description": "2.5 mg BAY94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY94-8862", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (5 mg )", 
                "description": "5 mg BAY94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY94-8862", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (7.5 mg)", 
                "description": "7.5 mg BAY94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY94-8862", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY94-8862 (10 mg)", 
                "description": "10 mg BAY94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY94-8862", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablet once daily in the morning", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY 94-8862 (15 mg)", 
                "description": "15 mg BAY 94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY 94-8862", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY 94-8862 (20 mg)", 
                "description": "20 mg BAY 94-8862 tablet once daily in the morning", 
                "intervention_name": "BAY 94-8862", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "BAY94-8862", 
            "MR antagonist", 
            "Diabetic nephropathy", 
            "Japanese patients"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "466-0815"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "456-0058"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saijo", 
                        "country": "Japan", 
                        "state": "Ehime", 
                        "zip": "793-0027"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kurume", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "830-8522"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kurume", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "830-8543"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Obihiro", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "080-0848"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amagasaki", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "660-0828"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koga", 
                        "country": "Japan", 
                        "state": "Ibaraki", 
                        "zip": "306-0232"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tsuchiura", 
                        "country": "Japan", 
                        "state": "Ibaraki", 
                        "zip": "300-0835"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tsukuba", 
                        "country": "Japan", 
                        "state": "Ibaraki", 
                        "zip": "305-0812"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kahoku-gun", 
                        "country": "Japan", 
                        "state": "Ishikawa", 
                        "zip": "920-0293"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakaide", 
                        "country": "Japan", 
                        "state": "Kagawa", 
                        "zip": "762-0007"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izumisano", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "598-8577"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yao", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "581-0011"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katsushika", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "125-0054"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "530-0001"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of urinary albumin-to creatinine ratio", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968668"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in serum potassium concentration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 90 days"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}